Abstract
Quadruplex nucleic acids are promising targets for cancer therapy. In this study we used a fragment-based approach to create new flexible G-quadruplex (G4) DNA-interactive small molecules with good calculated oral drug-like properties, based on quinoline and triazole heterocycles. G4 melting temperature and polymerase chain reaction (PCR)-stop assays showed that two of these compounds are selective G4 ligands, as they were able to induce and stabilize G4s in a dose- and DNA sequence-dependent manner. Molecular docking studies have suggested plausible quadruplex binding to both the G-quartet and groove, with the quinoline module playing the major role. Compounds were screened for cytotoxicity against four cancer cell lines, where 4,4′-(4,4′-(1,3-phenylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(1-methylquinolin-1-ium) (1 d) showed the greater activity. Importantly, dose–response curves show that 1 d is cytotoxic in the human colon cancer HT-29 cell line enriched in cancer stem-like cells, a subpopulation of cells implicated in chemoresistance. Overall, this study identified a new small molecule as a promising lead for the development of drugs targeting G4 in cancer stem cells.
Original language | English |
---|---|
Pages (from-to) | 1325-1328 |
Number of pages | 4 |
Journal | ChemMedChem |
Volume | 14 |
Issue number | 14 |
DOIs | |
Publication status | Published - 17 Jul 2019 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Funding
This work received funding from European Structural & Investment Funds through the COMPETE Program—Programa Opera-cional de Lisboa under Program grant LISBOA-01-0145-FEDER-016405, and from National Funds through Fundażo para a CiÞncia e Tecnologia (FCT) under Program grant SAICTPAC/0019/ 2015. J.B.V.’s research group was financed by New England Bio-labs, Inc. (USA). This work received funding from European Structural & Investment Funds through the COMPETE Program—Programa Operacional de Lisboa under Program grant LISBOA-01-0145-FEDER-016405, and from National Funds through Fundação para a Ciência e Tecnologia (FCT) under Program grant SAICTPAC/0019/2015. J.B.V.′s research group was financed by New England Biolabs, Inc. (USA).
Funders | Funder number |
---|---|
FCT - Fundação para a Ciência e a Tecnologia | |
New England Biolabs, Inc. | |
New England Bio-labs, Inc. | |
FCT - Fundação para a Ciência e a Tecnologia | SAICTPAC/0019/2015 |
Programa Operacional Temático Factores de Competitividade | LISBOA-01-0145-FEDER-016405 |
Keywords
- DNA
- G-quadruplexes
- cancer stem cells
- drug design
- heterocycles